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ABSTRACT 
Ovarian cancer remains a major problem of women’s health in the world, including Indonesia, and 
is associated with high rates of incidence and mortality. There are many efforts in early diagnosis on 
ovarian cancer, but until now there have not been found any satisfactory method. On the other hand, 
knowledge and research in the field of molecular biology become more advance, one of them is a 
mechanism to control the growth of cells in ovarian cancer through a process of programmed cell death or 
apoptosis. B-cell lymphoma protein 2 (Bcl-2) and caspase-3 are proteins that play a role on the mechanism 
of apoptosis. The purpose of this study was to determine the expression of Bcl-2 and caspase-3 and their 
association with ovarian cancer. Materials and method: The design of this study was a cross-sectional 
study. Expression of Bcl-2 and caspase-3 examined by immunohistochemistry under light microscope with 
400x light power field and expression as a negative when the protein expressed in 10% or less of cells and 
as a positive when the protein expressed in more than 10% of cells. A number of 45 subjects were recruited 
in this study. Thirthy one of 45 subjects showed the expression of Bcl-2 positive (68.9%), while the positive 
expression of caspase-3 present in 20 subjects (44.4%). There was a significant association between the 
expression of Bcl-2 with the expression of caspase-3 in ovarian cancer patients (p=0.002; lambda=0.4). 
There was also a significant association between stage of disease with expression of Bcl-2 (p=0.002; 
lambda=0.3) dan expression of caspase-3 (p=0.001; lambda=0.3). Conclusion: It concluded that there is a 
significant association between the expression of Bcl-2 and the expression of caspase-3 in ovarian cancer. 
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INTRODUCTION 
Over the past three decades, ovarian cancer 
remains a major problem of women’s health in the 
world, including Indonesia. It is associated with high 
morbidity and mortality that is caused by ovarian 
cancer. In the world, the incidence of ovarian cancer in 
2008 was 9.4%.
1,2
 The incidene rate ranks 7
th
 among 
cancers in women after breast cancer, colorectal, 
cervical, lung, stomach, and corpus uteri. Incidence 
rate of ovarian cancer ranks 3
rd
 among gynecologic 
cancers after breast and cervical cancer.
1
 Reports 
indicate that the incidence of ovarian cancer was 
varied. In 2008, the number of ovarian cancer cases in 
the United States is 21,650 cases
2
 and in the UK is 
6500 cases.
3
 While in Europe varies between 12 per 
100,000 women in Southern Europe and 19 per 
100,000 women in Northern Europe in 2008.
4
 
In Asia, the incidence of ovarian cancer is 
generally  lower  than the  population  in  Europe  and  
 
Correspondence: I N. G. Budiana 
Address: Obstetrics and Gynecologic Department, Faculty 
of Medicine, Udayana University, Bali-Indonesia 
Email: budiana@yahoo.com 
 
North America. In Japan, the incidence of ovarian 
cancer is increased since 1970, but still lower than 
western countries.
5
 Ushijima (2009) reported the 
incidence of ovarian cancer in Japan increased after 
the age of 60 become 10 per 100,000 women.
6
 In 
Indonesia, the incidence rate of ovarian cancer is 
uncertain. Based on report of Cancer Register Board 
Indonesian Ministry of Health that is obtained from 13 
Central Pathology Laboratory in Indonesia showed 
that the proportion of ovarian cancer is 4.9%.
7. 
Reports 
from some teaching hospital in Indonesia showed that 
the proportion of ovarian cancer ranged from 32.5% 
to 35%.
8,9
 
In addition to the high incidence rate, mortality 
rate of ovarian cancer is also high among gynecologic 
cancers. In the world, the rate of mortality of ovarian 
cancer in 2008 is 5.1%.
2
 The most important factor 
that influence the high mortality rate of ovarian 
cancer is 70-75% of cases diagnosed at an advanced 
stage even terminal where 5-year survival rate is 20 - 
of 30%. However, when found in stage I, the 5-year 
survival rate reach 90-95%.
10
 Thus, although the 
incidence of ovarian cancer was on the 3
rd
 place, but 
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the cancer is the number one cause of death among 
gynecological cancers. 
The difficulty of finding ovarian cancer at an early 
stage related to the difficulty of finding the accurate 
screening and early detection methods. There are 
many efforts in early diagnosis of ovarian cancer, but 
until now there have not been found a satisfactory 
methode. Screening modality such as ultrasound, 
tumor markers CA-125, α-fetoprotein, and other 
efforts have not been able to reduce the incidence 
and mortality rate of ovarian cancer. Similarly, several 
attempts therapy such as surgery, chemotherapy, and 
radiation, as monotherapy or combination has not 
been given satisfactory results. On the other hand, 
knowledge and research in the field of molecular 
biology is become more advanced. Ovarian cancer 
treatment through understanding of the carcinogenic 
mechanisms was more promising in the future. 
One mechanism to control cell growth is a 
process of programmed cell death or apoptosis. This 
mechanism is a complex process and involves a variety 
of proteins, i.e. Bcl-2 and caspase-3. Bcl-2 proteins 
work against the p53 tumor suppressors that disrupt 
cell cycle regulation. The cells will undergo 
proliferation and resistance to stimulation that would 
normally lead to cells death.
11
 Several studies have 
reported that expression of Bcl-2 in ovarian cancer 
was significantly higher than in benign tumor.
12
 
Meanwhile, caspase-3 protein is one of the 14 caspase 
that is known by human.
13
 Caspase-3 acts as an 
apoptosis executor and cell death due to specific 
stimuli. In addition, caspase-3 plays an important role 
in the changes in cell morphology and biochemical 
events associated with the implementation and 
complete the process of apoptosis.
14
 There is a 
significant difference in the expression of caspase-3 in 
epithelial ovarian cancer, borderline ovarian tumors, 
benign ovarian tumors, and normal ovarian tissue. 
Caspase-3 is also a factor of poor prognosis in 
epithelial ovarian cancer.
15
 
Studies of oncogenes, tumor suppressor genes 
and proteins involved in the process of apoptosis in 
ovarian cancer have been carried out. However, most 
research only focused on a single gene and in high-risk 
families so that the results are less representative in 
extrapolation. Protein expression of Bcl-2 and caspase-
3 are known to differ in malignant ovarian tumors, 
boderline, benign, and normal ovarian cells. However, 
no one has studied the relationship between 
expresion of these proteins in ovarian cancer. The 
relationship between protein Bcl-2 and caspase-3 is 
involved in apoptosis process will contribute to the 
role of both proteins in ovarian cancer carcinogenesis. 
In the future, a growing number of proteins are known 
to play a role in the carcinogenesis of ovarian cancer, 
there are more effort in screening method, early 
diagnosis, and genetic therapies that can be applied to 
reduce the incidence and mortality rate of ovarian 
cancer. 
 
METHOD 
This study is an observational study with cross-
sectional design. Subjects were patients with ovarian 
cancer tissues obtained from laparotomy surgery in 
Sanglah Hospital in Denpasar, which is based on 
histopathologic examination that is known as 
malignant ovarian tumors (ovarian cancer). Ovarian 
cancer classification refers to the classification of WHO 
in 2003.
16
 Ovarian tumors tissue that have parrafined 
and stored in Laboratory of Pathology Anatomi, 
Faculty of Medicine, Udayana University/Sanglah 
Hospital in Denpasar, which was diagnosed with 
ovarian cancer based on histopathological 
examination, was selected as research subjects. 
Inclusion criteria were: (1) a block of paraffin was 
examined histopathologically, so it was definitely 
diagnosed as ovarian cancer, (2) the patient's medical 
records can be found, and the necessary data is 
complete. While the exclusion criteria were: (1) 
patients who had been given chemo/radiotherapy 
preoperatively, (2) the tissue was damaged due to 
various technical reasons, (3) the patient's medical 
records could not be found or the necessary data was 
not complete. 
Ovarian cancer tissue that has been paraffined 
then processed for immunohistochemical examination 
of Bcl-2 and caspase-3 protein. Epidemiological data of 
patient is obtained secondary from patient’s medical 
records from data collection sheet. Examination of 
protein expression of Bcl-2 and caspase-3 was 
performed by immunohistochemistry. Bcl-2 protein 
expression examined using monoclonal antibody 
staining methode specific primary monoclonal mouse 
anti-human Bcl-2 protein clone 124, while caspase-3 
protein expression examined using biotin-avidin 
Indirect staining of primary mouse monoclonal 
antibody (Triton, Alameda, CA). Protein expression of 
Bcl-2 and caspase-3 was assessed semiquantitatively 
under light microscope with 400x light power light. 
Expresion was positive if protein was expressed in 
more than 10% of cells, whereas expression negative if 
protein was expressed in 10% or less of cells. 
 
RESULTS 
The number of subjects which is examined the 
expression of Bcl-2 and caspase-3 and a complete of 
patient’s medical record in the study as many as 45 
subjects. 
 
Characteristic of the subjects 
Of the 45 subjects, the youngest age is 19 years 
old and the oldest was 70 years old. Median age is 43 
years old with mean age of subjects was 41.3 ± 13.7 
years as indicate in Table 1. 
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Table 1 
Characteristic of the subjects 
 
Characteristic Total % 
Age (years)   
   ≤ 20 1 2.2 
   21-25 7 15.6 
   26-30 4 8.8 
   31-35 7 15.6 
   36-40 1 2.2 
   41-45 7 15.6 
   46-50 7 15.6 
   > 50 11 24.4 
Parity   
   0 22 48.9 
   1 5 11.1 
   2 8 17.8 
   3 4 8.9 
   4 2 4.4 
   > 4 4 8.9 
Histopatological type   
   Musinous 3 6.7 
   Endometrioid 3 6.7 
   Serous 26 57.8 
   Seromucous 1 2.2 
   Clear cell 1 2.2 
   Germ cell 6 13.3 
   Teratoma immature 2 4.4 
   Granulosa cell tumor 3 6.7 
Stage of disease   
   IA 4 8.9 
   IB 1 2.2 
   IC 14 31.2 
   IIC 1 2.2 
   IIIB 9 20.0 
   IIIC 10 22.2 
   IV 6 13.3 
 
The number of subjects that have parity are in 
the range of 0 - 9, with an average parity 1.5 ± 1.9. Of 
the 45 subjects, the commonest histopathological type 
was serous (57.8%). On the other hand, the rare 
histopathological type is clear-cell type and 
seromucous 2.2%, respectively.  
Ovarian cancer is kind of disease where the stage 
of disease is determined through surgery (surgical 
staging) according to the FIGO classification. From 45 
samples of the study, disease stage varies as shown in 
Table 1. No subjects suffering from ovarian cancer 
stage IIA, IIB, and IIIA. 
 
Bcl-2 and caspase-3 expression 
Distribution of subject based on Bcl-2 and 
caspase-3 expression was presented in Table 2. From 
this table it can be seen that 68.9 % was positively 
expressed Bcl-2 and 31.1 % was negatively expressed 
Bcl-2.  
Table 2 
Distribution of subjects by Bcl-2 and caspase-3 
expression 
Characteristic Total % 
Bcl-2 expression   
   Positive 31 68.9 
   Negative 14 31.1 
Caspase-3 expression   
   Positive 20 44.4 
   Negative 25 55.6 
 
Association between expression of Bcl-2 with 
expression of caspase-3 was presented in Table 3. 
 
Table 3 
Association between expresion of Bcl-2 with the 
expression of caspase-3 
 
 Expression of caspase-3 
Total p 
  Negative Positive 
Positive 22 9 31 0.002 
Expression of Bcl-2 
Negative 3 11 14  
Total  25 20 45  
Lambda=0.4 
 
Table 3 shows association between expression of Bcl-2 
to expression of caspase-3 (p=0.002; Lambda=0.4).  
 
Association between expression of Bcl-2 to stage of 
disease  
Table 4 shows the expression of Bcl-2 positive is 
increasing along with the stage of disease (p=0.002; 
Lambda=0.1). 
Tabel 4  
Distribution of subjects by stage of disease and Bcl-2 
expression 
Stage 
Bcl-2 expresion 
p 
positive negative 
IA 1 (3.2) 3 (21.5) 0.002 
IB 0 1 (7.1)  
IC 5 (16.1) 9 (64.3)  
IIC 0 1 (7.1)  
IIIB 9 (29.0) 0  
IIIC 10 (32.3) 0  
IV 6 (19.4) 0  
Total 31 (100) 14 (100)  
Lambda=0.3 
 
Association between expresion of caspase-3 with 
stage of disease  
Table 5 shows that the number of subject with 
positive expression of caspase-3 is getting  higher on 
early-stage disease, in contrast to subject with 
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advanced stage of disease showing negative 
expression of caspase-3 (p=0.000; Lambda=0.3). 
 
Table 5  
Distribution of subjects by stage of disease and 
caspase-3 expression 
 
Stage 
Caspase-3 expression (%) 
p 
Positive Negative 
IA 4 (20.0) 0 0.0001 
 IB 1 (5.0) 0 
IC 13 (65.0) 1 (4.0) 
IIC 0 1 (4.0) 
IIIB 0 9 (36.0) 
IIIC 2 (10.0) 8 (32.0) 
IV 0 6 (24.0) 
Total 20 (100) 25 (100)  
Lambda=0.3 
 
DISCUSSION 
Age 
In this study we found the proportion of ovarian 
cancer on age 20 years old for 2.2%, with the largest 
proportion in the age group over 50 years old. These 
results are similar with the data from SEER cancer 
statistic review that reported  between the years of 
2005-2009 the proportion of ovarian cancer at the age 
under 20 years old is 1.3%. While the largest 
proportion occurred in the age group of 55-64 years 
old as many as 23.4%.
17
 
These results are consistent with the reports in 
the published literature that stated the incidence of 
ovarian cancer is increased along with the age. 
Ovarian cancer is very rare occurred under 40 years 
old.
18
 Peak incidence of ovarian cancer occurs at age 
50 years old, and increasing gradually until 70 years 
old, then decline after 80 years old.
19
 
 
Parity 
Parity in this study ranged from 0-9. The largest 
proportion of patients with parity 0 is 48.9%. There is 
a trend of the larger parity proportion, the lower 
incidence of ovarian cancer, where parity that is more 
that 4 is as many as 8.9%. 
Research by Rivas-Corchado LM, et al.
 
found that 
from 40 ovarian cancer patients, 25% occurred in 
patients with parity 0.
20
 Another studies have found 
the risk of epithelial ovarian cancer is higher in women 
with higher social economy status. This is related with 
only a few of those women have childrends.
21
 Parity is 
a factor that increases the risk of ovarian cancer. The 
risk of ovarian cancer is decreased along with the 
increasing number of pregnancy.
18 
Multiparity 
associated with a reduced risk of ovarian cancer, 
where multiparity has relative risk of ovarian cancer 
0.6-0.8.
22
 
Protective effect against the development of ovarian 
cancer such as multiparity supports the concept of 
incessant ovulation which is a contributing factor in 
the development of ovarian cancer. This concept was 
first proposed by Fathalla.
23 
Risk of ovarian cancer is 
associated to the number of ovulatory cycles. When 
ovulation occurs, the epithelium surface was 
damaged. The epithelial damage stimulates epithelial 
cells to undergo proliferation as an attempt to repair. 
At the time of ovulation, also occurred invagination of 
epithelial surface into the stroma and form inclusion 
cyst.
18
 Subsequent researchers found that the process 
that involved in the repairment of damaged ovarian 
epithelial surface that caused by traumatic ovulation 
particularly epithelial that cover inclusion cyst under 
the influence of oncogenic factors somehow will turn 
to malignancy. The larger number of lifetime ovulatory 
cycles in women, the higher her risk of developing 
epithelial ovarian cancer.
24,25
 
 
Histopathological Type 
From 45 subjects, the commonest 
histopathologic type was serous (57.8%). On the other 
hand, rare of histopathologic type is clear-cell type 
and seromucous, 2.2% respectively.  
Research by Rivas-Corchado LM, et al. suggested 
the commonest histopathological type of ovarian 
cancer is serous that accounted for 25%, followed by 
endometrioid and mucinous types, 20% for each type 
and granulosa cell types 7%.
20  
While the granulose type is obtained with almost 
the same results, as many as 6.7 %. In other literature 
ovarian cancer serous type remains the commonest, 
accounted for 75%, followed by musinous (20%) and 
endometrioid (2%). While the type of clear-cell, 
Brenner, and undifferentiated carcinoma are less than 
1%, respectively.
16
 
 
Stage of disease 
Based on the stage of disease, from 45 subjects, 
there are no subjects with stage IIA, IIB, and IIIA. Stage 
1C has the largestproportion as many as 31.2%. In 
contrast with the results of study by Rivas-Corchado 
LM, et al. that found most cases in stage IA (32%). But 
cumulatively, the number of cases with advanced 
stage (stage III and IV) remains higher (55.5%) 
compared with early stage (stage I and II) as many as 
44.5%.
20
 
Report from ACOG Committee Opinion, 2002 
found that as many as 70-75% of ovarian cancer cases 
are diagnosed at advanced stage.
10
  
This is an important factor that affect the high 
mortality rate of ovarian cancer, where the 5-year 
survival rate at advanced stage is 20 - of 30%. 
However, when found in stage I, the 5-year survival 
rate reaching 90-95%.
10
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Association between Bcl-2 and Caspase-3 expression 
In this research, positive expression of Bcl-2 in 
ovarian cancer is 68.9%, while the negative expression 
of Bcl-2 31.1% (Table 3). The similar results also 
obtained in a cohort study with 95 advanced ovarian 
cancer patients (stage IIIC-IV), that found the results of 
immunohistochemical examination toward positive 
protein Bcl-2 rate of 69.5%.
26
 While other studies that 
involving 71 ovarian tumors serous, including 29 
benign ovarian tumors, 14 borderline ovarian tumors, 
and 28 malignant ovarian tumors found the positive 
expression of Bcl-2 17.2%, 35.7%, and 25%, 
respectively.
27
 
Meanwhile, the positive expression of caspase-3 
in this study is 44.4%, with the negative expression of 
caspase-3 is 55.6% (Table 2). These results are similar 
with results of other studies, which examine the 
expression of caspase-3 by immunohistochemistry in 
16 cases of benign ovarian tumors and 84 cases of 
ovarian cancer. Postive expression of caspase-3 is 
93.4% in benign ovarian tumors and 48.8% in cancer 
ovarium.
28
 Likewise, research on 112 cases of primary 
ovarian tumor, found positive caspase-3 expression in 
malignant ovarian tumors for 44, 4% which is 
significantly lower than the expression of caspase-3 in 
benign ovarian tumors that is 81.8% (p=0.01).
29
 The 
expression of caspase-3 in ovarian cancer are 
consistently lower than the expression of caspase-3 in 
benign ovarian tumor and normal ovarian tissue.
30, 31
 
In this study we also found a significant 
association between the expression of Bcl-2 with the 
expression of caspase-3 in ovarian cancer (p=0.002; 
lambda=0,4). Table 3 showed that in the group with 
positive expression of Bcl-2, we also found cases with 
negative expression of caspase-3. And vice versa, 
when there are group of negative expression of the 
Bcl-2, there are also cases with positive expression of 
caspase-3. This suggests a negative corelation cases 
with positive expression of Bcl-2 have negative 
expression of caspase-3, while the opposite cases with 
negative expression of Bcl-2 have a positive expression 
of caspase-3. 
On the mechanism of apoptosis, either through 
the extrinsic and intrinsic pathways, it is known that 
Bcl-2 acts as an anti apoptosis either through inhibit 
the release of cytochrome-c from mitochondria or by 
inhibiting the activity of caspase including caspase-3.
32
 
Caspase-3 is the most important executioner caspase 
among another executioner such as caspase-6 and 
caspase-7. Caspase-3 activity involved many 
substrates such as cytokeratin, PARP, fodrin 
cytoskeleton protein alpha plasma membrane, the 
protein core, and avtivate CAD 
endonuklease.
33
Activity of these proteins causes 
changes in morphology and biochemistry as seen in 
apoptotic cells include shrunken cells, protein 
condensation, chromosomal DNA fragmentation, 
degradation of the core including cytoskeleton 
proteins, and cells disintegration becoming apoptotic 
bodies.
14,34 
In the mechanism of apoptosis, Bcl-2 
activity is inversely proportional to caspase-3, where 
Bcl- 2 acts as an anti-apoptosis, while caspase-3 acts 
as executioner apoptosis. 
 
Association of Bcl-2 and caspase-3 expression with 
Stage of Disease 
When associated with stage of disease, there is a 
significant association between the expression of Bcl-2 
to stage of disease (p=0.002; lambda=0.3). Table 4 
showes the positive expression of Bcl-2 is increasing 
along with the higher stage of disease (p=0.002; 
Lambda = 0.3). Another studies found that the 
expression of Bcl-2 positively related to unfavorable 
factors such as the degree of differentiation of the 
cells, advanced stage disease, and residual tumor.
35
 
Meanwhile, Lukyanova NY, et al. found that the 
expression of  Bcl-2 is decreased in patients with 
ovarian cancer with a good degree of cell 
differentiation and in patients with early stage ovarian 
cancer.
36
 In contrast, the expression of Bcl-2 is 
increased along with the increasing degree of cell 
differentiation and stage of disease.
27 
This finding is 
consistent with the role of Bcl-2 in apoptosis 
mechanism as an anti-apoptotic as described above. 
Besides the association between the expression 
of Bcl-2 with stage of disease, the present study also 
found a significant association between the expression 
of caspase-3 with stage of disease (p=0.000). Table 5 
showed that the positive expression of caspase-3 is 
higher on the early-stage disease, in contrast to the 
advance stage that showed negative expression of 
caspase-3 (p=0.000; Lambda=0.3). Other studies have 
also found similar results, in which the expression of 
caspase-3 in malignant ovarian tumors is significantly 
associated with the degree of cell differentiation and 
stage of disease.
29-31
 In accordance with the role of 
caspase-3 in apoptosis mechanisms as an executioner 
caspase, then higher expression of caspase-3 means 
that the apoptotic mechanism went well. Conversely, 
if the expression of caspase-3 is low, apoptosis process 
will become impaired that will cause the stage of 
disease will be more advanced. 
 
CONCLUSION 
In this research, positive expression of Bcl-2 in 
ovarian cancer is 68.9%, while the expression of 
caspase-3 in ovarian cancer is 44.4%. Statistically, 
there is a significant association between the 
expression of Bcl-2 and the expression of caspase-3 in 
ovarian cancer. There was also a significant 
association between the expression of Bcl-2 and 
caspase-3 expression with stage ovarian cancer stage. 
The results of this study indicate a role of Bcl-2 and 
caspase-3 in ovarian cancer that can be used to 
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develop strategies for diagnosis, treatment, and 
prognosis based on molecular mechanism. Further 
research is needed with better research methods such 
as case-control or cohort study. 
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